Inflammatory/Immune Adverse Events in Chronic Myeloid Leukemia Patients During Treatment With Bosutinib

Inflammatory/Immune Adverse Events in Chronic Myeloid Leukemia Patients During Treatment With Bosutinib

ABSTRACT Background Bosutinib, a tyrosine kinase inhibitor (TKI), is effective in treating chronic myeloid leukemia (CML) patients resistant or intolerant to previous TKIs. Unlike other TKIs, bosutinib's lack of inhibition of c‐KIT and PDGFR may contribute to its unique tolerability profile. Si...

Full description

Saved in:
Bibliographic Details
Main Authors: E. Agostani, E. Tassistro, L. Antolini, C. Gambacorti‐Passerini
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:Cancer Medicine
Subjects:
bosutinib
CML
immune adverse events
SRC kinases
Online Access:https://doi.org/10.1002/cam4.70580
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items